Cargando…

Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against native-like vaccine and delta variant spike trimers

Traditional cellular and live-virus methods for detection of SARS-CoV-2 neutralizing antibodies (nAbs) are labor- and time-intensive, and thus not suited for routine use in the clinical lab to predict vaccine efficacy and natural immune protection. Here, we report the development and validation of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheedarla, Narayanaiah, Verkerke, Hans P., Potlapalli, Sindhu, McLendon, Kaleb Benjamin, Patel, Anamika, Frank, Filipp, Damhorst, Gregory L., Wu, Huixia, O’Sick, William Henry, Graciaa, Daniel, Hudaib, Fuad, Alter, David N, Bryksin, Jeannette, Ortlund, Eric A., Guarner, Jeanette, Auld, Sara, Shah, Sarita, Lam, Wilbur, Mattoon, Dawn, Johnson, Joseph M, Wilson, David H, Dhodapkar, Madhav V., Stowell, Sean R., Neish, Andrew S., Roback, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863158/
https://www.ncbi.nlm.nih.gov/pubmed/35194599
http://dx.doi.org/10.21203/rs.3.rs-1322411/v1
Descripción
Sumario:Traditional cellular and live-virus methods for detection of SARS-CoV-2 neutralizing antibodies (nAbs) are labor- and time-intensive, and thus not suited for routine use in the clinical lab to predict vaccine efficacy and natural immune protection. Here, we report the development and validation of a rapid, high throughput method for measuring SARS-CoV-2 nAbs against native-like trimeric spike proteins. This assay uses a blockade of hACE-2 binding (BoAb) approach in an automated digital immunoassay on the Quanterix HD-X platform. BoAb assays using vaccine and delta variant viral strains showed strong correlation with cell-based pseudovirus and live-virus neutralization activity. Importantly, we were able to detect similar patterns of delta variant resistance to neutralization in samples with paired vaccine and delta variant BoAb measurements. Finally, we screened clinical samples from patients with or without evidence of SARS-CoV-2 exposure by a single-dilution screening version of our assays, finding significant nAb activity only in exposed individuals. In principle, these assays offer a rapid, robust, and scalable alternative to time-, skill-, and cost-intensive standard methods for measuring SARS-CoV-2 nAb levels.